Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to be...
The Muscular Dystrophy Association (MDA) called the U.S. Food and Drug Administration’s approval of Itvisma (onasemnogene abeparvovec-brve), ...
Partnership accelerates AGC Biologics' leadership in the AAV market, applying its BravoAAV™ platform to complex gene therapies for inherited blin...
Data reveals positive preliminary results for investigational agent tinostamustine as a potential first-in-class treatment for glioblastoma. -...
New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced th...
In these diverse and dynamic markets, adaptation is not a strategy; it is a prerequisite for thriving. Success requires a fundamental shift in mind...
Initial commercial availability begins through an Early Experience Program with Penn Highlands Healthcare and Allegheny Health Network – Pr...
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...
Third Rock Ventures and Parse Biosciences announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, announced the official opening and ribbon c...
-Atomic launches today as a first-of-its-kind service offering for MedTech startups built to bridge the gap between breakthrough concepts and investor-re...
- March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, announced that the U.S...
Gnome Sciences, a molecular pathology and translational research services company, announced a significant advance in the fight against ALS (amyotrophic ...
Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in ...
© 2025 Biopharma Boardroom. All Rights Reserved.
